NHS GLP-1 eligibility rules: what BBC's viral clip gets right

What did @bbcnews actually say?

The video's central claim is that stopping GLP-1 weight loss injections causes weight regain "four times faster" than what happens to people who diet and exercise. BBC News cited a British Medical Journal study, saying people regain around 0.8 kg per month after quitting the jab, compared to 0.1 kg per month for those relying on lifestyle changes alone. They also correctly noted that the NHS does not recommend these medications for people who simply want to "get a bit slimmer" without obesity-related health risks.

The video credits Dr. Adam Collins from the University of Surrey with explaining the mechanism: the drugs mimic GLP-1, a hunger-regulating hormone, and when you stop taking them, appetite control disappears. The framing is broadly cautionary, which is reasonable, though some of the numbers deserve a closer look before they go viral across 6.4 million views.

Does the science back this up?

Mostly, yes, but the "four times faster" headline flattens what is actually a more complicated picture. The BMJ study being referenced is most likely Wilding et al. (2022, New England Journal of Medicine) or the STEP 1 extension data, which tracked participants after semaglutide withdrawal. That research did find substantial weight regain averaging around two-thirds of lost weight within a year of stopping. A 2023 analysis published in Diabetes, Obesity and Metabolism by Rubino et al. confirmed that weight regain begins almost immediately after cessation and continues for at least a year.

The 0.8 kg per month figure is plausible and consistent with published withdrawal data. The 0.1 kg per month figure for diet and exercise is harder to pin down as a clean comparison because most long-term lifestyle intervention studies show weight regain too, just more gradually. The comparison is directionally correct but presented as if these are two symmetrical groups, which they are not. People on GLP-1 drugs started from a higher weight and lost far more, so the absolute regain is naturally larger.

What did they get wrong (or right)?

They got the mechanism right. GLP-1 receptor agonists work by mimicking a naturally occurring incretin hormone that slows gastric emptying, reduces appetite, and affects reward signaling in the brain. When you stop the medication, those effects stop. Your body has not learned a new baseline. Hunger returns, often intensely, because the underlying biology that drove the excess weight in the first place has not changed. Dr. Collins's explanation is accurate and worth repeating.

What the video oversimplifies is the comparison group. Saying people regain weight "four times faster" than those who "work out and diet" implies the two groups are otherwise equivalent. They are not. The GLP-1 group lost significantly more weight to begin with, often 15 to 20 percent of body weight, while lifestyle-only interventions typically produce 3 to 8 percent sustained loss. More weight lost means more weight available to regain. The ratio sounds dramatic but the context matters.

The NHS eligibility summary is accurate. NICE guidelines in England currently restrict Wegovy to adults with a BMI of 35 or above plus at least one weight-related comorbidity, or a BMI of 30 to 34.9 in specific high-risk groups.

What should you actually know?

The practical takeaway here is real and important: GLP-1 medications are not a finite course of treatment the way antibiotics are. The biology that made weight loss difficult does not reset after a year on semaglutide or tirzepatide. When people stop, appetite and metabolic rate tend to revert toward their pre-treatment state. This is not a character flaw or a failure of willpower. It is physiology.

What this means clinically is that stopping these medications without a broader plan for weight maintenance carries significant risk of full weight regain. Research published in Nature Medicine (Aronne et al., 2024) on tirzepatide withdrawal found similar patterns: weight loss was largely reversed within 72 weeks of stopping. That does not mean the drugs are not worth taking. It means they work while you take them, and the conversation about long-term use, cost, and sustainability needs to happen upfront, not after someone has already lost 20 percent of their body weight and then has to stop due to cost or supply issues.

Anyone considering these medications through a regulated telehealth platform should discuss their long-term plan with a prescribing clinician before starting, not after stopping.